This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

SNBB active ingredient pharma cartel fined 600,000 francs in Switzerland

( April 10, 2025, 07:44 GMT | Official Statement) -- MLex Summary: Drugmakers Boehringer Ingelheim, Alkaloids of Australia, Alkaloids Corporation, Alchem, C2 Pharma, Linnea and Transo-Pharm agreed to fix the minimum sale price of active ingredient butylscopolamine bromide, or SNBB, to allocate quotas, and to exchange information. The conduct lasted for fourteen years, the Swiss Competition Commission said today. While C2 Pharma received full immunity from the fine, Transo-Pharm and Linnea won partial immunity from their sanctions. This is the first time the office fined a cartel in that sector with regard to an active ingredient. SNBB is an important ingredient to produce antispasmodic drugs for stomach pains. Statement follows. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections